Iovance Biotherapeutics Inc (IOVA)

[MN Gopher]

GMH, Thanks for finding my error. Confusion on the end of 1st Qtr.
The numbers I posted are for the 2nd & 3rd Qtr’s.

I did post the high end of the spectrum, Im an eternal optimist with Iovance.

I follow the Science & The $ in something like Amtagvi. The top Biotech Investor in our lifetimes is in charge of Iovance & knows EXACTLY what it takes to execute the game plan in real time.

In my opinion, we are blessed beyond comprehension with Wayne leading the charge in helping to Cure Cancer & Find us a Triple Figure Buyout.

Wayne will not make any mistakes in our sale & valuation. He is The Best in the Business.

The Science is what 35-40 years old with Stephen A. Rosenberg being Ground Zero in his steadfast belief Solid Tumor Cancer Tumors could be Cured (Partial Cures too, my addition)

https://ccr.cancer.gov/staff-directory/steven-a-rosenberg

We have to me Apple One equivalent
The beginning of a life transforming Treatment that will be improved upon, Licensed to other BP or BioTech Companies to continue on humanities quest to Cure Cancer.

We will use genetic modifications to possibly improve upon our treatments.

This in theory translate to “Cure” many other Solid Tumor Applications, World Wide. We will in my opinion be FDA Approved one day for many, many solid tumor applications.

We will move to front line in my opinion soon on Melanoma combining Amtagvi with Keytruda.
Our stats show together in Phase 3 study, 66.7% in combo.
This alone crushes our 31.4 Amtagvi FDA accelerated approval for last line of D in use today, alone without Keytruda.

Think Merck: Keytruda Exclusivity ends in 2028. This is their Cash Cow.
Imagine Merck buying Iovance (in 2025/26 in my opinion) n extending Keytruda’s Exclusivity useage piggybacking with Amtagvi Treatments. Iovance with its approved 4 Yr exclusivity extension at the end of their 14 yr exclusivity tagteams them to 2042!

This company is now in say the equivalent
Of a 10 month old kid.

Its the beginning of a world wide expansion for TIL/Amtagvi in Clinical/ Hospital Use in their own ATC’S.

Wayne Rothbaum is a special Biotech investor man. He has long term relationships in Biotech & Buyouts well established prior to Iovance.

His expertise & relationships tell me one thing: Think Acerta & We Are Up Next.

Im adding as many shares at every dip I can.

#CureCancer